Monotherapy Or Chemotherapy Adjunct: Pembrolizumab In Advanced NSCLC

Welcome to NewMedicalTerms, your ultimate guide to the explanations and definitions of the majority of medical terms you may see.

Monotherapy Or Chemotherapy Adjunct: Pembrolizumab In Advanced NSCLC Objectives To assess the effectiveness and safety of pembrolizumab monotherapy and in combination with chemotherapy in patients with advanced non–small-cell lung cancer (NSCLC).  Introduction Historically, patients with advanced NSCLC have a poor prognosis despite the use of platinum-based chemotherapy drugs. The 5-year relative survival rate of

Sinonasal B‐cell lymphomas: A Cohort Study on Progression and Recurrence

Welcome to NewMedicalTerms, your ultimate guide to the explanations and definitions of the majority of medical terms you may see.

Sinonasal B‐cell lymphomas: A Cohort Study on Progression and Recurrence STUDY BACKGROUND Sinonasal lymphoma is a rare malignancy of rhinologic origin affecting the sinonasal region and surrounding structures. It is a type of non-Hodgkin lymphoma (NHL) comprising around 1.5% of all lymphomas and usually involves males aged between 40 and 70 years.

Inoperable locally advanced non-small cell lung cancer: Survival rates of Endostar, CCRT

Welcome to NewMedicalTerms, your ultimate guide to the explanations and definitions of the majority of medical terms you may see.

Inoperable locally advanced non-small cell lung cancer: Survival rates of Endostar, CCRT Inoperable locally advanced non-small cell lung cancer (NSCLC): An Introduction Accounting for approximately 80% of lung cancers, non-small cell lung cancer (NSCLC) is the most common subtype. Most NSCLC patients are diagnosed at an advanced stage with a mere 15-20%

Monotherapy Or Chemotherapy Adjunct: Pembrolizumab In Advanced NSCLC